 | |
| Clinical data | |
|---|---|
| Other names | Aureolic acid; Mithracin; Antibiotic LA 7017; Mithramycin A; Mitramycin; Plicatomycin |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.162.065 |
| Chemical and physical data | |
| Formula | C52H76O24 |
| Molar mass | 1085.156 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Plicamycin (INN, also known asmithramycin; trade nameMithracin) is anantineoplasticantibiotic produced byStreptomyces plicatus. It is an RNA synthesis inhibitor.[1] The manufacturer discontinued production in 2000. Several different structures are currently reported in different places all with the same chromomycin core, but with different stereochemistry in the glycoside chain, a 1999 study has re-investigated the compound and proposed a revised structure.[2]
Plicamycin has been used in the treatment oftesticular cancer,[3][4]Paget's disease of bone,[5][6] and, rarely, the management ofhypercalcemia.
Plicamycin has been tested inchronic myeloid leukemia.[7]
Plicamycin is currently used in multiple areas of research, including cancer cell apoptosis[8] and as a metastasis inhibitor.[9]
One elucidated pathway shows it interacts by cross-bindingchromatin GC-rich promoter motifs, thereby inhibitinggene transcription.[10]